Rationale: People living with HIV are at significantly increased risk of invasive pneumococcal disease, despite long-term antiretroviral therapy (ART). The mechanism explaining this observation remains undefined.
HIV-1-seropositive individuals have a significantly increased risk of pneumococcal disease that persists despite antiretroviral therapy (ART), even after CD4
1 T-cell reconstitution (1, 2) . Alveolar macrophages (AM) are essential for pneumococcal clearance from the lung (3) yet evidence of modulation of AM immune competence against pneumococci by HIV-1 has proven elusive; opsonic phagocytosis of pneumococci is preserved during HIV-1 infection (4) and although defective phagolysosomal killing is reported for some pathogens, it has not been demonstrated for pneumococci (5) .
The capacity of healthy human tissue macrophages to destroy extracellular bacteria through internalization and phagolysosomal killing is finite (6) , and AM need to engage a second, delayed microbicidal strategy involving apoptosisassociated killing to eliminate residual viable intracellular pneumococci, which involves combinations of reactive oxygen species (ROS) and nitric oxide (3, (7) (8) (9) . The apoptotic program is regulated by the antiapoptotic Bcl-2 protein Mcl-1 and induction of a mitochondrial apoptosis pathway (10) . Apoptosis-associated killing enhances clearance of pneumococci, limits tissue invasion, and downregulates the inflammatory response in the lung (10, 11) . Importantly, HIV-1 is associated with an antiapoptotic gene expression profile in monocytes in vivo and promotes macrophage resistance to apoptosis, which contributes to these cells constituting a viral reservoir for HIV-1 (12) (13) (14) (15) .
We addressed whether HIV-1 prevents engagement of the apoptotic program required for pneumococcal killing. Here, we report a selective deficit in delayed, apoptosis-associated pneumococcal killing in AM from ART-treated HIV-1-seropositive volunteers. We document evidence of low-level viral replication and gp120 detection in the lung despite long-term suppressive ART and confirm that HIV-1 envelope glycoprotein gp120 is sufficient to inhibit macrophage killing of pneumococci in human monocyte-derived macrophages (MDM), through altered post-translational regulation of Mcl-1 and failure to induce mitochondrial ROS (mROS) generation.
Some of the results of these studies have been previously reported in the form of an abstract and doctoral thesis (16, 17) .
Methods
Additional detail on the method for making these measurements is provided in the online supplement.
Bacteria, Virus, and Infections
Opsonized, type 2 Streptococcus pneumoniae (D39 strain, NCTC7466) were used for infection of macrophages at a multiplicity of infection of 10 unless otherwise stated, as described (10) . In some infections, autologous peripheral blood lymphocytes or HIV-1 LAI/IIIB envelope glycoprotein gp120 (National Institute for Biological Standards and Control) at 10-100 ng/ml were added to MDM. HIV-1 BaL (NIH AIDS Reagent Program) was propagated in peripheral blood lymphocytes, then MDM, and purified before cell inoculation. Infection rates were measured by intracellular p24 staining as described (18) .
Volunteers
Healthy, never-smoker, hepatitis B and C virus negative, HIV-1-seropositive patients either established on ART or ART naive (used as comparator for BAL and virology studies) were recruited from the HIV clinic of STH for bronchoscopy along with matched HIV-seronegative volunteers, described in Table 1 .
Cell Isolation and Culture
Peripheral blood mononuclear cells were isolated from whole blood of healthy donors and differentiated to MDM (10) . Nonadherent peripheral blood mononuclear cells were enriched for CD8 1 T lymphocytes by negative selection and more than 95% purity confirmed by flow cytometry. CD8
1 T lymphocytes were added 1:1 to MDM. Cells were isolated from BAL fluid as described (4) .
Western Blot
Whole-cell extracts were isolated using sodium dodecyl sulfate lysis buffer and separated by sodium dodecyl sulfate gel electrophoresis.
Flow Cytometry
Cell surface marker expression was measured by flow cytometry with fluorophoreconjugated antibodies or isotype controls. MDM mROS was measured using MitoSOX-Red (Invitrogen), and loss of Dc m was measured with JC-1 (Molecular Probes).
Microscopy
Nuclear fragmentation and condensation indicative of apoptosis were detected using 4969-diamidino-2-phenylindole (10) . BAL cells were identified on stained cytospins.
Caspase Activation
Cellular caspase activity was measured using Caspase-Glo 3/7 (Promega) according to the manufacturer's instructions. Luminescence was measured on a Varioskan Flash microplate analyzer (Thermo Scientific).
Quantification of gp120
BAL supernatants were concentrated using 50k Amicon Ultra-filters (Merck Millipore) and gp120 quantified with human monoclonal anti-gp120 antibodies (14E, 17B, and EH21), using recombinant gp120 (HIV-1 LAI/IIIB ) for standards, by ELISA as described (19) .
Metabolic Measurements
Oxygen consumption rate and extracellular acidification rate were measured using the XF24 extracellular flux analyzer (Seahorse Bioscience) as described (20) .
RT-PCR Array
AM gene expression was measured after 48 hours with a custom made RT 2 Profiler PCR Array (SABiosciences) using qPCR. 
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Ultrasensitive Detection of HIV-1 RNA in BAL BAL HIV-1 RNA was quantified using a modified version of the Abbott RealTime HIV-1 assay (Maidenhead), after ultracentrifugation similarly to methods in plasma samples (21) . After confirming no inhibition, sensitivity was determined at one to two copies per milliliter by spiking acellular HIV-negative BAL with World Health Organization Third International HIV-1 RNA Standard (National Institute for Biological Standards and Control).
Statistics
Results are recorded as mean and SEM unless stated. Sample sizes were informed by standard errors obtained from similar assays in prior publications (10, 20) . Analysis was performed with tests, as outlined in the figure legends, using Prism 6.0 software (GraphPad Inc.) and significance defined as P less than 0.05. Decisions on use of parametric or nonparametric tests were informed by the distribution of the data. 
Results
HIV-1 Inhibits Delayed Pneumococcal Killing by Macrophages
To examine whether HIV-1 influences macrophage killing of pneumococci, we infected MDM with HIV-1 BaL , an M-tropic stain of HIV-1 (18), or sham virus ( Figure 1A ) and then, after adjusting for cell numbers, challenged MDM with pneumococci. The numbers of viable intracellular bacteria in MDM 4 hours after bacterial challenge, which are the net result of opsonic phagocytosis and phagolysosomal killing (4), were unaltered by HIV-1 BaL ( Figure 1B) . By contrast, 20 hours after pneumococcal challenge the intracellular bacterial load was higher in HIV-1 BaL MDM ( Figure 1C ). When we examined engagement of the MDM apoptotic program, we found that caspase 3/7 activation, development of apoptotic nuclei, and loss of cell numbers after pneumococcal challenge were significantly reduced by HIV-1 BaL compared with sham infection (Figures 1D-1F ). Mcl-1 was downregulated in sham virus-exposed MDM, but levels were preserved in HIV-1 BaL MDM ( Figures 1G and 1H ). Despite comparable mitochondrial density, HIV-1 BaL MDM had elevated production of mROS after mock infection but, unlike sham virus-exposed MDM, failed to upregulate mROS after pneumococcal challenge ( Figures 1I and 1J (Figures 2A and 2B ). AM in these samples also showed reductions in caspase 3/7 activation, numbers of apoptotic nuclei, and cell loss relative to healthy control subjects ( Figures 2C-2E ). The impairment of apoptosis after pneumococcal challenge was not related to use of protease inhibitors or nonnucleoside reverse transcriptase inhibitors as the third ART agent ( Figure 2F ). When we investigated the relationship between the number of HIV-1 BaL -infected MDM and apoptosis induction after pneumococcal challenge, we found no correlation ( Figure 2G ). We next investigated if steady state expression of representative genes associated with apoptosis and polarization was altered in AM from our donor groups. Using quantitative PCR arrays, we found that although there was an overall trend toward downregulation of gene expression in AM from ART-treated HIV-1-seropositive individuals compared with healthy control subjects, no consistent differences in the expression of these genes was observed Third ART agent PI 6 n/a n/a NNRTI 7 n/a n/a Mixed/other regimen 1 n/a n/a Duration, mo 75 (43-108)* Definition of abbreviations: ART = antiretroviral therapy; n/a = not applicable; NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor. Data are shown as n or mean 6 SEM unless otherwise indicated. *Median (interquartile range). (see Figure E1 in the online supplement). Furthermore, representative markers of macrophage polarization states CD80 (M1), CD163, CD206, and CD200r (M2) also showed no significant alteration in surface expression in AM from HIV-1-seropositive individuals on ART (see Figure E2 ). Figure E2 ). In addition, we found that the ratio of
1 T lymphocytes in BAL correlated with the induction of AM apoptosis, after pneumococcal challenge ( Figure 3F ). We next explored whether T-lymphocyte CD38 expression, a marker of immune activation in HIV-1 that correlates with viral load (23) , was increased in the ART-treated HIV-1-seropositive donors. However, CD8
1 T lymphocytes showed no difference in CD38 expression ( Figure 3E ). We also tested whether in vitro activated, autologous CD8
1 T lymphocytes could alter MDM engagement of apoptosisassociated killing but found no modulation of MDM viability, apoptosis, or intracellular bacterial survival (see Figures E3A-E3C ). ) and numbers of viable intracellular bacteria determined (*P , 0.05, unpaired Student's t test). (C-E) Alternatively, HIV-1-seropositive or control AM were exposed to D39 or mock infected for 16 hours, and caspase 3/7 activity was measured (C) (n = 5/11, *P , 0.05, unpaired Student's t test); or HIV-1-seropositive or control AM were exposed to D39 or mock infected for 20 hours, and nuclear features of apoptosis were recorded (D) or cell numbers assessed (E) (both n = 8/14, **P , 0.01, ***P , 0.001, two-way ANOVA). (F) Nuclear features of apoptosis in AM were determined separately from HIV-1-seropositive donors who had used nonnucleoside reverse transcriptase inhibitor or protease inhibitor exclusively as the third antiretroviral therapy agent (n = 7/6). (G) HIV-1 BaL or sham virus-exposed monocyte-derived macrophages (MDM) were challenged with D39 for 20 hours, and apoptosis was assessed by nuclear morphology. The value for the HIV-1 BaL apoptosis increment was subtracted from the value for the sham virus-exposed MDM increment to calculate the D% apoptosis and plotted against the percentage of p24-positive MDM, measured by immunohistochemistry (n = 13). CFU = colony-forming units; HPF = high-powered field; MI = mock infected; NNRTI = nonnucleoside reverse transcriptase inhibitor; ns = not significant; PI = protease inhibitor.
The CD4:CD8 ratio in ART-treated HIV-1-seropositive individuals is inversely related to the size of the HIV-1 reservoir in the peripheral blood (24) . Therefore, we considered an alternative possibility, that BAL CD4:CD8 ratio was a marker of persistent HIV-1 replication in the lung; we detected HIV-1 p24 in AM cultures from two of two ART-naive and 3 of 10 ART-treated HIV-1-seropositive donors, respectively ( Figure 3G ). Using ultrasensitive assays HIV-1 RNA was detected at 79 copies/ml and 1-4 copies/ml of cell-free BAL fluid supernatants from 1 of 1 ART-naive and 2 of 13 (15.4%) ART-treated HIV-1-seropositive donors, respectively. However, the number of donors with detectable p24 or RNA were too few to determine any correlation between these markers of HIV replication and the BAL CD4:CD8 ratio. We detected HIV-1 envelope glycoprotein (gp120) in a 10-100 ng/ml range in BAL fluid from 5 of 11 (45.5%) of the ARTtreated and in 1 of 2 ART-naive HIV-1-seropositive donors tested, and observed that those on ART with detectable gp120 also had significantly lower peripheral blood CD4 1 counts ( Figure 4A ). Recombinant gp120 recapitulated the selective deficit in delayed-phase pneumococcal killing by MDM ( Figures 4B  and 4C ) and reduced both numbers of apoptotic nuclei and caspase 3/7 activation after pneumococcal challenge ( Figures 4D  and 4E ). gp120 was also associated with a baseline increase in mROS, without altering mitochondrial density, but gp120-exposed MDM failed to upregulate mROS after pneumococcal challenge (Figures 4F and  4G ). mROS production was abrogated by MitoTEMPO, a mitochondria-targeted superoxide dismutase mimetic that possesses superoxide and alkyl radical scavenging properties, confirming mitochondria as the source of ROS ( Figure 4F ).
When we analyzed the bioenergetic response of MDM, we observed that pneumococcal challenge led to an increase in baseline extracellular acidification rate and a reduction in maximal oxygen 
test). (B-D)
Monocyte-derived macrophages were treated with 10 ng/ml gp120 or media and then challenged with Streptococcus pneumoniae (D39), and viable consumption rate, and this switch in metabolism was unaltered by gp120 ( Figures  4I-4L ). Pneumococcal challenge resulted in increased proton leak across the inner mitochondrial membrane ( Figure 4M ). However, this response and the loss of mitochondrial inner transmembrane potential (Dcm) were diminished by gp120 ( Figure 4H ). We next analyzed whether abrogation of mROS upregulation, with an mROS inhibitor MitoTEMPO, altered intracellular pneumococcal killing. After challenging MDM with pneumococci, we observed no difference in the number of viable intracellular bacteria after 4 hours in the presence of gp120 or mitoTEMPO. However, addition of MitoTEMPO to control MDM increased bacterial survival at 20 hours to the same level seen with gp120 but had no effect on viability in gp120-exposed MDM at two distinct multiplicities of infection ( Figure 5 ). 6D) . Ubiquitination of Mcl-1 is tightly regulated and ubiquitination is reversed by the de-ubiquitinase USP9X (25) . We detected decreased expression of USP9X after pneumococcal challenge in control MDM, but treatment with gp120 abrogated this response ( Figures 6E  and 6F ).
Discussion
Here, we demonstrate for the first time that HIV-1 impairs pneumococcal killing by macrophages. We show HIV-1 is associated with specific defects in the late phase of pneumococcal killing by impairing apoptosis induction and reducing caspasedependent induction of mROS. Critically, we find this defect in AM from HIV-1-seropositive individuals established on long-term ART with good immune reconstitution. Furthermore, despite extended periods of ART, we find evidence of altered cellular immune responses, viral replication, and release of the HIV-1 envelope glycoprotein gp120 in the lungs. gp120 is sufficient to reprise the deficit in pneumococcal killing and does so via altered post-translational regulation of Mcl-1, a key regulator of macrophage apoptosis.
AM are essential for pneumococcal clearance; they initially resist proapoptotic stimuli while engaging phagolysosomal bacterial killing but subsequently activate apoptosis, which facilitates bacterial clearance while minimizing inflammation (3, 10) . We found that HIV-1 BaL impaired host-mediated MDM apoptosis during pneumococcal infection and this was associated with a failure to clear internalized pneumococci. Mcl-1 levels were maintained in the HIV-1 BaL -infected MDM after pneumococcal challenge while caspase 3/7 activation was reduced, indicating that the mitochondrial pathway of apoptosis, implicated in bacterial killing, was impaired (3, 10) . This extends prior observations implicating HIV-1 in altered regulation of Bcl-2 family proteins (13, 26) .
Caspase 3 activation promotes release of mROS by inhibiting the mitochondrial electron transport complex I and has been identified as a requirement for the increment of mROS generation that is required to mediate apoptosis-associated killing of intracellular pneumococci (20, 27) . The failure of HIV-1 BaL -infected MDM to increase mROS production over baseline after pneumococcal challenge resulted in pneumococcal survival, similar to recent observations in AM from patients with chronic obstructive pulmonary disease (COPD) (20) . In contrast to the requirement for a late increment in mROS to achieve optimal intracellular killing, chronic baseline elevation of mROS, after HIV-1 or gp120 exposure, does not seem to enhance intracellular bacterial killing. Consistent with this an inhibitor of mROS had no impact on early intracellular bacterial viability at 4 hours. COPD AM also show chronic baseline elevation of intracellular mROS but no enhancement of early intracellular bacterial killing (20) . To play a role in intracellular killing, mROS needs to be generated in proximity to bacteria in phagolysosomes (20, 28) and be produced at levels above baseline after caspase 3 activation to overwhelm antioxidant systems (20) . In COPD, there is not only reduced caspase 3/7 activation but also an altered balance between mROS generation and superoxide dismutase 2 expression, which suggests increased ability to neutralize baseline mROS. Recent observations show gp120 also upregulates superoxide dismutase in microglia (29) . It is noteworthy that, like COPD, HIV-1 has been associated with chronic increases in oxidative stress in mononuclear phagocytes, despite ART (30, 31) , and adaptions to this in both conditions are predicted to impair the capacity to generate a microbicidal response.
HIV-1 infects and replicates in macrophages and, while establishing a longlived cellular viral reservoir (15) , induces resistance to apoptosis (12, 26) . Our finding that HIV-1 infection is linked to intrinsic impairments in macrophage apoptotic responses is supported by previous studies with Mycobacterium tuberculosis (32), but to the best of our knowledge ours is the first report of impaired killing of pneumococci or any other acute extracellular bacterial infection. Crucially, we have confirmed our findings in clinically relevant AM Figure 4 . (Continued). intracellular bacteria (colony-forming units) were estimated after 4 hours (B) and 20 hours (C) (n = 15, *P , 0.05, paired Student's t test); or nuclear features of apoptosis were estimated after 20 hours of incubation and compared with mock infection (D) (n = 8, *P , 0.05, two-way ANOVA). (E-M) Alternatively, monocyte-derived macrophages were treated with 100 ng/ml gp120 or media and then challenged with D39 or mock infected for 16 hours before quantifying caspase 3/7 activity (E) (n = 7, *P , 0.05, paired Student's t test); mitochondrial reactive oxygen species, in the presence or absence of MitoTEMPO (mT) (F) (n = 4-8, **P , 0.01 two-way ANOVA, # P , 0.005 Mann-Whitney test [vs. no mT]); mitochondrial density (G) (n = 4); or loss of mitochondrial inner transmembrane potential (Dc m ) (H) (n = 3, *P , 0.05, **P , 0.01, two-way ANOVA); or using a Seahorse XF24 extracellular flux analyzer to measure oxygen consumption rate (I) and extracellular acidification rate (K) and calculate maximum oxygen consumption rate (J), basal extracellular acidification rate (L), and proton leak (M) (all n = 6, *P , 0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001, two-way ANOVA). AntA = antimycin A; CFU = colony-forming units; ECAR = extracellular acidification rate; FCCP = carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon; MFI = median fluorescence intensity; MI = mock infection; ns = not significant; OCR = oxygen consumption rate; Oligo = oligomycin A; Rot = rotenone.
from aviremic HIV-1-seropositive individuals.
Untreated, HIV leads to AIDS and increased rates of opportunistic infection, including bacterial pneumonia and invasive pneumococcal disease (33) . Although ART inhibits viral replication, reconstitutes cellmediated immunity, and dramatically reduces opportunistic infection, invasive pneumococcal disease remains 35-fold and bacterial pneumonia 20-fold more common in HIV-1-seropositive individuals in the era of ART (2, (34) (35) (36) . Our findings suggest that persisting defects in the macrophage microbicidal response contribute to this risk of pneumococcal disease.
We hypothesized that the observed reductions in delayed bacterial killing were caused by indirect effects of HIV-1; only a minority of AM in ART-naive individuals are infected with HIV-1 (37) and, furthermore, within 24 weeks of ART initiation there are large reductions in both BAL fluid RNA and cell-associated HIV-1 nucleic acid (38) . Our volunteers had received a median of 75 months ART and had no HIV-1 RNA detectable in peripheral blood by standard assays. Our in vitro MDM model allows manipulation of the percentage of MDM that are positive in a culture (18) , and we saw no association between the rate of direct MDM HIV-1 infection and apoptosis. Macrophage effector functions are influenced by their activation status (39) and AM from ARTnaive HIV-1-seropositive individuals show classical (M1) activation (37, 40, 41) . However, when we measured the activation status and transcriptome of AM from our virally suppressed HIV-1 donors, we found no difference from healthy control subjects. Although the plasticity of macrophages makes it conceivable that differences in activation and gene transcription could be lost during AM isolation and culture (40, 42) , we conclude that once established on long-term ART, HIV-1-seropositive have no persisting changes in transcriptional pathways regulating AM activation.
T lymphocytes influence early macrophage-mediated innate immune responses to pneumococci in the airway (22) . Consistent with prior reports (38) , ART-naive individuals had increased lymphocyte numbers in BAL fluid, but, surprisingly, we also observed persistent lymphocytosis in the BAL of individuals receiving ART. Furthermore, they had a lower CD4:CD8 T-lymphocyte ratio that correlated with altered AM apoptosis. This is a noteworthy finding because low CD4: CD8 ratios in the peripheral blood of ARTtreated HIV-1-seropositive individuals are linked to non-AIDS morbidity, immune activation, inflammation, and heightened CD8 1 T-lymphocyte activation (43) .
Although there may be a role for specific subsets of CD8 1 T lymphocytes influencing AM behavior in the lung, we found no elevated CD38 expression on BAL T lymphocytes and no effect on apoptosis or bacterial killing when we explored the influence of activated CD8
1 T lymphocytes on MDM responses to pneumococci in vitro. Thus these suggest that global changes in CD8
1 T lymphocytes are a biomarker of intermittent low-level viral replication but do not directly mediate the inhibition of macrophage apoptosisassociated bacterial killing.
We also found evidence for ongoing viral replication in the lungs of some ARTtreated individuals by either directly detecting viral RNA, p24 in AM, or gp120 in BAL samples. These results add to the observation that potentially replicationcompetent virus persists in lung AM despite long-term ART (44) and extend reports of detectable gp120 in histologic lung specimens of virally suppressed individuals (45) . This study measured a snapshot of viral RNA and gp120 and was not powered to detect a relationship between these markers of viral replication and the BAL lymphocyte count or CD4:CD8 ratio. However, the persistence of altered BAL CD4:CD8 T-cell ratios is more likely to be a function of cumulative periods of episodic HIV replication in the lung with normalization of this ratio requiring sustained suppression of viral replication, as described in the peripheral blood (24) .
We have been able to demonstrate that recombinant gp120 is sufficient to recapitulate the impairment in delayed phase pneumococcal killing related to HIV-1 infection. HIV-1 envelope (gp120) has been shown to be necessary for macrophage resistance to apoptosis acutely after a single cycle of replication with X4-or R5-tropic HIV-1 (13), whereas gp120 when disassociated from virus, is sufficient to influence macrophage function and apoptosis resistance (14, 46, 47) . Importantly, we observed this effect at concentrations of gp120 both similar to those we found in the BAL and commensurate with those described in other anatomic compartments in HIV-1-seropositive individuals (46) .
As with HIV BaL , we observed a failure of gp120-treated MDM to downregulate Mcl-1. Mcl-1 is regulated by ubiquitination and proteasomal degradation (9). gp120 treatment also induced basal mROS but prevented further generation of mROS in response to caspase 3/7 activation after pneumococcal challenge. When we interrogated the bioenergetic response of MDM, we observed a switch to glycolytic metabolism after pneumococcal challenge in keeping with a greater reliance on glycolytic metabolism during innate immune responses associated with classical activation in macrophages. We also observed increased proton leak, which is predicted to enhance mROS generation because under these conditions complex I is inhibited by caspase activation (27) . However, both the uplift in proton leak and loss of mitochondrial inner membrane potential were diminished by gp120. Taken together these results indicate that despite raised baseline levels gp120 reduces caspaseinduction of mROS, a critical microbicidal effector (20, 27, 28) .
In conclusion, our findings suggest specific defects in the late phase of pneumococcal killing by AM contribute to the sustained increase in susceptibility to pneumococcal disease in people living with HIV. Furthermore, despite long-term ART, we find evidence of viral replication resulting in release of gp120 in the lungs associated with HIV-1. Through Mcl-1-mediated inhibition of apoptosis, gp120 reduces caspase-dependent induction of mROS and its important microbicidal effects (20) . Significantly, the inhibition of apoptosis was not part of a global shift in transcriptional networks regulating cell viability but arose in response to impairment of a critical post-translational pathway that regulates macrophage viability. Because the pathway involves ubiquitination of Mcl-1, and is associated with a critical Mcl-1 deubiquitinase USP9X (25) , this pathway merits investigation as a potential therapeutic target. n . (E and F) Alternatively, cells were lysed at 20 hours and blotted for USP9X. In each case, a representative Western blot is depicted with the result of densitometry performed on three separate Western blots with data shown as fold change in band density compared with mock-infected control MDM after adjustment for any fold change in loading control (*P , 0.05, **P , 0.01, two-way ANOVA). MI = mock infected; Ub = ubiquitin. 
